Based on its recent analysis of the therapeutic peptides market, Frost & Sullivan recognises Peptisyntha with the 2011 Europe Frost & Sullivan Award for Enabling Technology. Continued research of potentially cost-effective and novel applications of technologies for peptide production is indicative of Peptisyntha’s ever-expanding competencies.
“Peptisyntha is one of the few suppliers that can provide high quality, cGMP-compliant therapeutic peptide products and services at competitive prices to customers in the pharmaceutical and biotechnology industries,” notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. “A versatile and innovative technology portfolio has enabled Peptisyntha to implement various synthesis processes, customised to suit customer-specific needs.”
Key technologies include Silylation technology used in peptide synthesis, Tetraphenylborate (TBP) technology for the synthesis of Arginine-rich peptides, world class manufacturing processes of non-natural amino acid building blocks and others such as the use of Phenyl-oxy-carbonyl-protection (Phoc-AA) of amino acids/ peptides in the coupling reaction.
Silylation technology enables working with non-protected amino acids and peptide fragments, thereby reducing the need for protection and de-protection steps. This, in turn, translates into saving of labour, resources and cost as well as optimal equipment utilisation.
Tetraphenylborate technology aids the cost-effective manufacturing of Arginine- and Lysine-rich peptides, such as anti-microbial peptides and cell penetrating peptides. The LHRH or GnRH peptides produced using Peptisyntha’s exclusive TPB technology, are a well-known class of therapeutic peptides manufactured cost effectively by Peptisyntha. These peptides find use in several therapeutic domains, including the treatment of hormone-dependent cancers and fertility control.
“Peptisyntha’s proprietary technologies enable cost-effective production of APIs by increasing yield and purity, reducing the number of chemical steps, avoiding racemisation” remarks Aiswariya Chidambaram. “The technologies offered by Peptisyntha are highly flexible, as they are not limited to one typical product line, but can be used for a wide range of peptide APIs spanning all therapeutic areas.”
Currently, the company is working on two projects based on advanced peptide biomaterials using peptide self-assembling properties. Firstly, peptide hydrogels for cell culture and, secondly, peptide-based biomaterials for sustained/controlled drug release.
“With peptide-dedicated laboratories, kilo labs, pilot and commercial scale manufacturing units, Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs,” concludes Aiswariya Chidambaram. “The company has excelled in delivering its technology to market participants by ensuring optimal peptide purity, quality yield, development timeline and affordable pricing” Said Dr. Johan Devenyns, Managing Director of Solvay Peptides. “This Award is the result of more than two decades of efforts and innovation to contribute to our customers’ success around the globe. Performance and expertise combined with innovative solutions lead to this competitive advantage our customers are benefitting from” added Dr. Mimoun Ayoub, Vice President Global Business & Strategic Developments.
The Enabling Technology Award is presented to the company that has demonstrated success in enabling the creation of new products, enhancing current products and enabling new applications. Other criteria according to which the company was selected as the award recipient include potential for market acceptance and breadth of access to technology.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Peptisyntha (peptisyntha.com) is a leading cGMP manufacturer of therapeutic peptides (peptide APIs) and peptidomimetics serving customers from the pharmaceutical, biotech, diagnostic and cosmetic industries.
With 25 years of experience in peptide manufacturing Peptisyntha provides a seamless portfolio of expertise from lead optimization to commercial cGMP manufacturing. With two GMP manufacturing facilities in USA and Belgium, Peptisyntha masters all manufacturing technologies (SPPS, LPPS and hybrid approaches) at all scales Peptisyntha is a wholly owned company of Solvay, an international chemical group active in chemistries contributing to improving quality of life.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.